A Phase 3 study of the Qnaze beclamethasone nasal spray from Teva has demonstrated that the product produced significant symptom relief compared to placebo, according to a Teva presentation at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). Qnaze is a "dry" HFA intranasal formulation delivered by MDI and intended to treat seasonal allergic rhinitis. Read the company’s press release.
Teva announces positive Phase 3 results for Qnaze nasal spray
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK